Study: Gleevec may boost efficacy of stroke therapy

06/22/2008 | Reuters

An international team of scientists who induced stroke in mice found that those that received Novartis AG's leukemia drug Gleevec experienced 33% less blood vessel leakage linked to tissue plasminogen activator, a clot-dissolving drug. The findings suggest that Gleevec may help reduce tPA-related adverse events and increase the number of patients who could receive the stroke therapy. The researchers plan to begin human trials of the drug combination in the next few months.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA